Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D000068342:Aspirin, Dipyridamole Drug Combination; D000077144:Clopidogrel; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000068342:Aspirin, Dipyridamole Drug Combination; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin